New and Emerging Treatments in Cutaneous Vasculitis

Cleveland Clinic Rheumatology

C. Langford

Checkpoint Inhibitors and Rheumatic Disease

NYU Langone

A. Bass

EADV 2023 Insights: Infectious Granulomatous Skin Diseases

EADV 2023 Insights

E. Laffitte

When Should Biologic Agents be Considered in Eosinophilic Granulomat…

Cleveland Clinic Rheumatology

M. Wechsler

EGPA: Challenges and Prognosis

Cleveland Clinic Rheumatology

R. Hajj-Ali

Could EGPA be Treated with Biologics?

Cleveland Clinic Rheumatology

M. Wechsler

Eosinophilic Granulomatosis with Polyangiitis with Persistent Shortn…

Cleveland Clinic Rheumatology

A. Villa-Forte

EULAR 2023 Insights: Benralizumab for Eosinophilic Granulomatosis wi…

EULAR 2023 Insights

A. Bettiol

Immunomodulatory Drugs (IMIDs) Advances in Disease Pathogenesis

Cleveland Clinic Rheumatology

W. Rigby

EGPA: Look Carefully at the Heart

Cleveland Clinic Rheumatology

W. Tang

Lupus And a New FDA Approval for EGPA

RheumNow

J. Cush

Are There Factors That Can Guide Treatment Decisions in Newly Diagno…

Cleveland Clinic Rheumatology

A. Villa-Forte

Pathergy in Patients with Bechet's Disease Receiving Laser Hair Remo…

Evidence-Based Hair

J. Donovan

Giant Cell Arteritis in the Arab Region With a Focus on Jordan

Fatima Al Naimat

Great Debate (PMR/GCA) - Upfront Use of IL-6 Inhibitors

Hospital for Special Surgery

R. Spiera, P. Seo

Behçet Syndrome Diagnosis: How and When Do Major/Minor Clinical Mani…

Haner Direskeneli

Diagnosis of Giant Cell Arteritis

Houston Methodist DeBakey Heart and Vascular Center

S. To

Behcet Syndrome Update: How Does It Manifest? When Do Symptoms Typic…

Yusuf Yazici

Abstract Discussions: Osteoporotic Fractures in Postmenopausal Women…

RheumNow

J. Pope

GCA & Steroid Weaning

RheumNow

J. Cush